Key Dates

Related Announcements

NOT-HD-22-038 - Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

PAR-21-155 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)

PAR-21-154 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)

PAR-21-357 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

PAR-22-060 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA).

The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of:

• emerging and evolving public health crises; and/or
• policy changes

on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see https://nida.nih.gov/about-nida/strategic-plan/nidas-mission.

History

The NIDA has a long-term interest in research on the effects of emerging and evolving public health crises and policy changes on its populations of interest. This Notice is meant to formally establish that research on these topics is of high programmatic interest to the NIDA, and to obviate the need for individual NOSIs on public health crises and policy changes as they emerge.

Scope

Emerging and evolving public health crises (hereafter, public health crises) include, in addition to emerging epidemics and pandemics, the sequalae of both natural and man-made disasters. Past and current examples are the Zika Virus (ZIKV) and the COVID-19 pandemic, Hurricane Katrina, and the events of September 11, 2001.

Policy changes include changes achieved through legislation, legal decisions, or executive actions. Recent examples include the Affordable Care Act (ACA) and the pandemic-related eviction moratorium.

This Notice applies to health, development, and well-being outcomes that are within the scientific scope of the NIDA. This Notice does not apply to research on outcomes that are the focus of other NIH Institutes and Centers.

While this Notice is primarily focused on policy change and public health crises that are national in scope or, at a minimum, affect a large share of the U.S. population, there is no requirement that research submitted in response to this Notice be national or regional in scope. Research focused on outcomes in specific locations are also permitted if the results can be generalized to the United States overall, a large segment of the U.S. population, a major U.S. subpopulation, or a health disparities population.

Priority Research Areas for NIDA

• Impact of policies and public health crises that have limited windows of opportunity for planning and conducting rigorous research and data collection on mitigating substance use risk, delaying substance use initiation, and reducing substance misuse, substance use disorder, and associated consequences.
• Use of wastewater epidemiology to answer questions related to emerging public health crises and policy changes.
• Implementation of public health policies to protect health and prevent substance use, including state and local regulations, community enforcement, and workforce training.
• Impact of policies intended to improve social determinants of health and other risk factors on substance use risk and misuse behaviors.
• Impact of public health crises and policy changes on the availability and access to licit and illicit substances and related outcomes including changes in use prevalence, overdose patterns, and impacts on other substance use (e.g., cannabis and alcohol delivery and curbside pick-up during the pandemic, etc.).
• Impact of policies that establish and monitor legal cannabis markets in order to prevent youth cannabis use, including market requirements; dispensary locations, hours, workforce training, and/or other standards; tax rates and use of tax revenue; and other statutes, regulations, and enforcement mechanisms.
• Impact of policies that support the development of substance use prevention systems, including financing strategies, workforce, community collaboration, and other systems.
• Evaluation of strategies to support policymaker, health system, and other stakeholder decision-making to implement evidence-based policies and interventions.
• Impact of public health crises and policy changes on the availability of health services (e.g., mental health services, substance use treatment and counseling, etc.) and related outcomes, with a particular focus on health disparities (e.g., increased availability of telehealth and changes in policies for distributing MAT for opioid use disorder, etc.).
• Impact of emerging public health crises and policy changes on underserved populations that address the causes, consequences, and reduction of health disparities and related outcomes as it relates to substance use risk and misuse behaviors

Applicants are strongly encouraged to discuss potential applications with the Scientific/Research Contact listed below before submitting their application.

Application and Submission Information

This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. 

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

• PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed

• PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

• PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

• PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

• PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

• PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

• PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

• PAR-21-155 Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)

• PAR-21-154 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)

• PAR-21-357 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

• PAR-22-060 - Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-DA-22-084” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Elyse R. Grossman
National Institute on Drug Abuse (NIDA)
Telephone: 240-551-3628
Email: elyse.grossman@nih.gov